Which drugs should be avoided while using Vigabatrin (Ocoda)?

Drug interactions are an issue that requires special attention during use of Vigabatrin. Vigabatrin is a γ-Aminobutyric acid (GABA) metabolism inhibitor, through irreversible inhibition of GABAAminotransferase (GABA-T) increases the concentration of GABA in the central nervous system, thereby exerting anti-epileptic effects. Since its mechanism of action is related to a variety of central nervous system drugs, if used simultaneously with certain drugs, it may increase the risk of adverse reactions or affect the efficacy.

First of all, avoid simultaneous use with other drugs that enhance central depressant effects , such as benzodiazepines (diazepam, lorazepam), barbiturates (phenobarbital) and some sedative-hypnotics. Combined use may result in excessive sedation, drowsiness, cognitive function decline or respiratory depression, especially in elderly patients or those with hepatic and renal insufficiency.

Secondly, Vigabatrin should not be used randomly with Other anti-epileptic drugs (such as sodium valproate, lamotrigine) unless the dose is adjusted under the guidance of a doctor. Although combinations of certain antiepileptic drugs may enhance efficacy, inappropriate combinations may increase neurotoxicity, visual impairment, or burden on liver function. Therefore, risks and benefits should be assessed before combination therapy, and blood drug concentrations and retinal function should be monitored regularly during treatment.

Finally, it is important to note that the absorption and metabolism of Vigabatrin may be affected by carbonic anhydrase inhibitors (such as acetazolamide) or diuretics . Certain drugs may alter blood electrolyte balance or renal excretory function, thereby affecting the concentration of Vigabatrin in the body and increasing the risk of neurotoxicity. While using Vigabatrin, patients should provide their doctors with a complete medication list, including prescription drugs, over-the-counter drugs and health care products, so that the treatment plan can be adjusted appropriately and avoid potential drug conflicts.

Reference link:https://www.drugs.com